Aspergillosis Treatment Market Players:
- Bayer AG
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- WOT Analysis
- Mayne Pharma Group Limited
- PULMATRiX Inc.
- Endo International plc
- Johnson & Johnson Services Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Abbott
- Takeda Pharmaceutical Company Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of aspergillosis treatment is evaluated at USD 4.53 billion.
The global aspergillosis treatment market size exceeded USD 4.35 billion in 2025 and is set to expand at a CAGR of around 4.5%, surpassing USD 6.76 billion revenue by 2035.
North America aspergillosis treatment market is projected to capture a 42% share by 2035, driven by high prevalence of lung diseases, HIV, and organ transplants.
Key players in the market include Bayer AG, Mayne Pharma Group Limited, PULMATRiX Inc., Endo International Plc, Johnson & Johnson Services Inc., GlaxoSmithKline Plc, Pfizer Inc., Abbott, Takeda Pharmaceutical Company Limited, Novartis AG, Shionogi & Co., Ltd., Asahi Kasei Pharma Corporation, F2G Ltd., Regeneron Pharmaceutical Inc.
